Noxon, a MedTech company based in Munich and a spin-off from three renowned universities, has successfully closed its seed funding round. The round was led by High-Tech Gründerfonds (HTGF) and Bayern Kapital, two of the leading venture capital investors in Germany and Europe, together with Auxxo and another institutional investor. The capital will be used to advance the clinical validation and certification of Noxon’s non-invasive Muscle-Computer Interface and to prepare for the market launch of its first therapy modules.
Addressing Gaps in Muscle Diagnostics and Rehabilitation
In rehabilitation and for neuromuscular disorders, muscle diagnostics and activation are traditionally performed only sporadically and under clinical conditions. As a result, patients lack continuous data and adaptive therapy in their daily lives throughout the treatment process.
Introducing a Wearable Muscle-Computer Interface
Noxon addresses this gap with a medical Muscle-Computer Interface that, for the first time, combines continuous muscle diagnostics and neuromuscular electrical stimulation (NMES) in a wearable suitable for everyday use. The key innovation lies in the closed feedback loop of real-time measurement and personalized muscle and nerve activation over the course of therapy, seamlessly integrated into existing products such as tapes, patches, and orthopedic aids.
Expanding Clinical Applications
Noxon is also collaborating with leading medical partners, including the University Hospital Würzburg and the neuroscience group N-Squared Lab, on additional pilot applications. The focus is on supporting muscle control when signal transmission between the brain and muscle is impaired, such as with solutions that reduce tremor in Parkinson’s patients.
“Neurological and musculoskeletal diseases are on the rise globally. Healthy muscle function is fundamental, yet often overlooked, and existing solutions tend to be too complex or costly,” says Maria Neugschwender, CEO of Noxon. “The support from HTGF and Bayern Kapital enables us to further validate our platform technology clinically and bring our first products to market. Our goal is to make muscle health transparent, personalized, and affordable for everyone.”
Dr. Lena-Sophie Schütter, Investment Manager at HTGF, adds: “What I find so compelling about Noxon is how effective therapy can become as simple as applying a bandage. The Muscle-Computer Interface platform gives patients the opportunity to regain mobility and independence, from preventing muscle atrophy to reducing Parkinson’s tremor. That’s a true advance for quality of life.”
Monika Steger, Managing Director of Bayern Kapital, comments: “Noxon’s technology platform, which enables human muscles to be both ‘read’ and then stimulated and activated, holds significant potential across a range of applications, particularly in therapy and medical rehabilitation. Based on this approach, conditions that are currently difficult to treat, such as Parkinson’s or paralysis, could be addressed more effectively and gently for patients. This would represent major value for both medical technology and healthcare as a whole, making Noxon a very promising investment.”